Delivery Order #HT942726FE025

Delivery Order for OctaplasLG Units to US Marine Corps

This award represents a delivery order contract for the purchase of a substantial quantity of OctaplasLG units intended for the United States Marine Corps. The contract recipient, Octapharma USA, Inc., is a leading pharmaceutical company specializing in plasma-derived therapies. The order procures 1,500 units of OctaplasLG, a plasma product used in critical care and transfusion medicine, underscoring its importance for military medical readiness and patient care. The scope includes timely delivery of these plasma units to support the Corps' operational health needs, with performance scheduled over a multi-month period. This delivery order is linked to a broader indefinite delivery vehicle contract previously awarded to Octapharma USA, which authorizes provision of OctaplasLG powder and related sterile medical supplies under FDA Emergency Use Authorization. The award highlights continuity and reliability in supply for vital biological products to the Department of Defense. Awarding was through a contract vehicle enabling efficient procurement, supporting defense healthcare logistics without the need for new competition at this stage. The contract period spans several months in the year 2026, ensuring prompt fulfillment of the Marine Corps' plasma product requirements.

Description

PURCHASE OF 1,500 OCTAPLASLG UNITS FOR THE UNITED STATES MARINE CORP

View original record